Editorial

793 The therapeutic window of opportunity in rheumatoid arthritis: does it ever close?
K Reza, A Filer

Viewpoint

795 Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity
M Hughes, J B Lilleker, A L Herrick, H Chinoy

Criteria

799 Evidence-based provisional clinical classification criteria for autoinflammatory periodic fever

Clinical and epidemiological research

806 Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts
J A van Nieuw, R Tomsas, A Gaspard-Vaude, B Faure, A H M van der Helm-van Mil

813 Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis
L Edert, A Thavaneswaran, V Changtan, R J Cook, D D Gladman

818 Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)
C O Bingham III, W Rezzi, A Kott, A Hassounah, R Upmanyu, M Klearman

823 Enthesitis in patients with psoriatic arthritis, axial spondyloarthritis and healthy subjects assessed by ‘head-to-toe’ whole-body MRI and clinical examination
R F Poggenborg, J Esched, M Oosterba, I J Sorensen, J M Møller, O R Nielsen, S F Pedersen

830 Development of a health index in patients with ankylosing spondylitis (ASSA HI): final result of a global initiative based on the ICF guided by ASAS
U Kilt, D van der Heijde, A Brandt, A Cesca, C Stucki, M A Khan, W P Maksymowych, H Marzo-Ortega, J Møller, S Stengaard-Pedersen, M L Hetland, J Hennings, K Stengaard-Pedersen, A M Cuttica, J Braun

835 Impact of alliporinil on risk of myocardial infarction

843 Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
J S Smolen, P Emery, G F Ferraccioli, W van den Beucken, F Borden, O R Davies, W Koenig, O Pumariega, B Bennett, H Burkhart

851 Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens
M Franzen, M Agellen, L Nairn, M Vorurue, L Bédrigue, S Sue, S Jan, L March, J Edmonds, R Norton, M Woodruff, B Day, on behalf of the LECS study collaborative group

859 Validation of EULAR primary Spörgen’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)

867 A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial

876 Predicting the severity of joint damage in rheumatoid arthritis: the contribution of genetic factors
M W van Steenbergen, B Janssens, T WJ Huijtinga, S le Cessie, A H M van der Helm-van Mil

883 Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis
J A van Nieuw, M W van Steenbergen, A Krye, W Stemp, T WJ Huijtinga, M Rejnars, A H M van der Helm-van Mil

890 Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
K Otsdjonio, J Askelin, J Ekoben, E E Krenstien, V Elven, Hullen van, for the AKTS group

897 The specificity of ultrasound-detected bone erosions for rheumatoid arthritis
A S Zayat, K Kugel, P C Cuningham, T Tarsley, E M A Hendro, J F Eastron, P Emeary, R J Waterfield

Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>793</td>
<td>The therapeutic window of opportunity in rheumatoid arthritis: does it ever close?</td>
</tr>
<tr>
<td>795</td>
<td>Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity</td>
</tr>
<tr>
<td>799</td>
<td>Evidence-based provisional clinical classification criteria for autoinflammatory periodic fever</td>
</tr>
<tr>
<td>806</td>
<td>Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts</td>
</tr>
<tr>
<td>813</td>
<td>Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis</td>
</tr>
<tr>
<td>818</td>
<td>Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)</td>
</tr>
<tr>
<td>823</td>
<td>Enthesitis in patients with psoriatic arthritis, axial spondyloarthritis and healthy subjects assessed by ‘head-to-toe’ whole-body MRI and clinical examination</td>
</tr>
<tr>
<td>830</td>
<td>Development of a health index in patients with ankylosing spondylitis (ASSA HI): final result of a global initiative based on the ICF guided by ASAS</td>
</tr>
<tr>
<td>835</td>
<td>Impact of alliporinil on risk of myocardial infarction</td>
</tr>
<tr>
<td>843</td>
<td>Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial</td>
</tr>
<tr>
<td>851</td>
<td>Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens</td>
</tr>
<tr>
<td>859</td>
<td>Validation of EULAR primary Spörgen’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)</td>
</tr>
<tr>
<td>867</td>
<td>A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial</td>
</tr>
<tr>
<td>876</td>
<td>Predicting the severity of joint damage in rheumatoid arthritis: the contribution of genetic factors</td>
</tr>
<tr>
<td>883</td>
<td>Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis</td>
</tr>
<tr>
<td>890</td>
<td>Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register</td>
</tr>
<tr>
<td>897</td>
<td>The specificity of ultrasound-detected bone erosions for rheumatoid arthritis</td>
</tr>
</tbody>
</table>

More CONTENTS ▶
Recent infections are associated with decreased risk of rheumatoid arthritis: a population-based case-control study
M E C Sandberg, C Bengtsson, I Klareskog, L Alfredsson, S Stårvardsson

Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study
N Dalbeth, M E House, O Aati, P Tan, C Franklin, A Horne, G D Gamble, L K Stamp, A J Doyle, F M McQueen

Basic and translational research

Autophagy is activated in systemic lupus erythematosus and required for plasmablast development
A J Clarke, U Ellinghaus, A Cortini, A Stranks, A K Simon, M Bone, T J Vyse

Angiogenic T cells are decreased in rheumatoid arthritis patients
J Rodríguez-Carro, M Alperi-López, P López, S Alonso-Castro, F J Bollina-Carda, A Sánchez

Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis
L Yeo, H Lom, M Juárez, M Snow, C D Buckley, A Filer, K Raza, D Scheel-Toellner

Inhibition of casein kinase II reduces TGFβ-induced fibroblast activation and ameliorates experimental fibrosis

Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease
E L Culver, E Vermeulen, M Makwana, A van Leeuwen, R Sadler, T Carrell, P Klenertman, R C Audibert, S M van Ham, E Barnes, T Ruytens

Letters

Unifocal psoriatic arthritis development in identical twins following site specific injury: evidence supporting biomechanical triggering events in genetically susceptible hosts
J Ng, A L Tan, D McGonagle

Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system
J N Stoop, A Fischer, S Hayer, M Hegen, T WJ Huizinga, G Steiner, L A Trouw, R E Toes

Electronic pages

Correspondence

e33 Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?
M Boers

e34 Response to: ‘Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?’ by Dr Boers
C Roubille, V Richer, T Starnino, C McCourt, A McFarlane, P Fleming, S Siu, J Kraft, C Lynde, J Pope, W Culliver, S Keeling, J Dutz, L Bessette, R Bissonnette, B Haraoui

e35 Does MOVES move the needle?
R Meyer

e36 Response to: ‘Does MOVES move the needle?’ by Dr Meyer
M C Hochberg, on behalf of the MOVES Investigation Group

e37 Is chondroitin sulfate plus glucosamine superior to placebo in the treatment of knee osteoarthritis?
C Zeng, J Wei, G-h Lei